Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

PMV Pharma's Rezatapopt Achieves 44% Response Rate in TP53 Y220C Ovarian Cancer

2 September 2026 · By · Wire by Fusion42

Published

2 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at clinicaltrialvanguard.com →

◆ Verified

Fusion42 · 2 September 2026 · Fusion42 review

PMV Pharma's Phase 2 PYNNACLE trial shows rezatapopt monotherapy achieving a 44% response rate in heavily pretreated ovarian cancer patients with the TP53 Y220C mutation, supporting a potential FDA accelerated approval based on biomarker-defined response data.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You now have a clear regulatory path using biomarker-defined patient selection to gain accelerated FDA approval before full survival data. If you target rare mutations in oncology, this approach can speed your market entry.

◆ Coverage

1 source · 2 Sep 2026

◆ Related on Wire

◆ Topics

Biotechoncologyclinical-trialtargeted-therapyfda-approvaltp53-mutation